These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33420642)

  • 1. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
    Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
    Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers.
    Wu M; Li X; Sun J; Chen H; Ding Y
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):503-508. PubMed ID: 33535835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
    Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
    Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults.
    Pierce D; Corcoran M; Velinova M; Hossack S; Hoppenbrouwers M; Martin P
    Drug Des Devel Ther; 2015; 9():1257-68. PubMed ID: 25767373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
    Wu J; Gießmann T; Lang B; Elgadi M; Huang F
    J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
    Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers.
    Du P; Long Y; Wang M; Huang Y; Wang Y; Chen X; Lin Y; Wu J; Shen J; Jia Y
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):251-257. PubMed ID: 38703321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
    Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
    J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
    Bækdal TA; Breitschaft A; Navarria A; Hansen CW
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):869-877. PubMed ID: 29897249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study of drug-drug interaction between omeprazole and pyrotinib after meal.
    Li X; Wang Y; Zhu X; Zheng L
    Br J Clin Pharmacol; 2022 May; 88(5):2349-2358. PubMed ID: 34873745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
    Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Hwang KG; Kim YS; Shaw LM; Lee YS; Kang JS
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):23-9. PubMed ID: 19203529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
    Patel G; Gupta VK; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149522. PubMed ID: 36943038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
    Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects.
    Sun F; Liu Y; Li T; Lin P; Jiang X; Li X; Wang C; Gao X; Ma Y; Fu Y; Cao Y
    BMC Pharmacol Toxicol; 2023 Feb; 24(1):7. PubMed ID: 36737825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.